Comparison of impurity profiles – and problematic HCPs – in mAbs
Have you ever wondered if there are trace amounts of problematic host cell proteins (HCPs) - or other process-related impurities - in marketed antibody drugs?
Or, how similar the HCP profile of a mAb biosimilar is to the originator?
Alphalyse used a unique mass spectrometry-based assay to analyze and compare HCPs in more than 50 mAbs, including 16 commercial mAbs. We now present the results from the study:
Join Rikke Lund online to hear about the analytical method and the HCPs identified – and also learn which potentially problematic HCPs we found in several of the mAbs.